Radcliffe Capital Management’s Eucrates Biomedical Acquisition Corp. Warrant EUCRW Stock Holding History

Radcliffe Capital Management’s Portfolio EUCRW Stock Details EUCRW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-33,333	Closed	-$1.21K	–	684
2023 Q1	$1.21K	Hold	33,333	–	–	﹤0.01%	683
2022 Q4	$333K	Hold	33,333	–	–	0.01%	803
2022 Q3	$334K	Hold	33,333	–	–	0.01%	1104
2022 Q2	$330K	Hold	33,333	–	–	0.01%	1159
2022 Q1	$329K	Hold	33,333	–	–	0.01%	1157
2021 Q4	$325K	Hold	33,333	–	–	0.01%	1004
2021 Q3	$326K	Hold	33,333	–	–	0.01%	856
2021 Q2	$328K	Hold	33,333	–	–	0.01%	879
2021 Q1	$333K	Buy	+33,333	New	+$54K	0.01%	663

Radcliffe Capital Management's EUCRW Position: Q2 2023 in Review

Radcliffe Capital Management sold out of Eucrates Biomedical Acquisition Corp. Warrant (EUCRW) in Q2 2023, closing a stake of 33,333 shares — an estimated $1.21K sold.

Radcliffe Capital Management first reported a position in EUCRW in Q1 2021 and held it in 9 quarters. The position peaked at $334K in Q3 2022. 0 funds tracked by Wall St. Rank hold EUCRW as of Q2 2023.

Radcliffe Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Warrant position as of Q2 2023 after selling out during the quarter.
Radcliffe Capital Management sold 33,333 Eucrates Biomedical Acquisition Corp. Warrant shares in Q2 2023, an estimated $1.21K.
Radcliffe Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Warrant in Q1 2021 and held it in 9 quarters.
Radcliffe Capital Management's Eucrates Biomedical Acquisition Corp. Warrant position peaked at $334K in Q3 2022.
0 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Warrant as of Q2 2023.

Based on Radcliffe Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.